Liminatus Pharma Inc. (NASDAQ:LIMN) Sees Large Decline in Short Interest

by · The Cerbat Gem

Liminatus Pharma Inc. (NASDAQ:LIMN – Get Free Report) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totaling 120,590 shares, a drop of 46.1% from the November 30th total of 223,895 shares. Based on an average daily volume of 137,849 shares, the short-interest ratio is currently 0.9 days. Approximately 0.4% of the shares of the stock are sold short. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 137,849 shares, the short-interest ratio is currently 0.9 days.

Liminatus Pharma Price Performance

Liminatus Pharma stock traded down $0.06 during trading on Friday, hitting $0.65. The company’s stock had a trading volume of 184,407 shares, compared to its average volume of 126,256. The stock has a fifty day moving average price of $1.02. Liminatus Pharma has a 1-year low of $0.61 and a 1-year high of $33.66. The stock has a market capitalization of $17.52 million and a PE ratio of -5.39.

Liminatus Pharma (NASDAQ:LIMN – Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.07) EPS for the quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on LIMN shares. Wall Street Zen downgraded shares of Liminatus Pharma from a “hold” rating to a “strong sell” rating in a report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Check Out Our Latest Stock Report on Liminatus Pharma

Liminatus Pharma Company Profile

(Get Free Report)

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Featured Stories